Great Lakes Advisors LLC Sells 2,941 Shares of Thermo Fisher Scientific Inc. $TMO

Great Lakes Advisors LLC decreased its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 1.4% in the 3rd quarter, according to its most recent 13F filing with the SEC. The firm owned 202,384 shares of the medical research company’s stock after selling 2,941 shares during the quarter. Great Lakes Advisors LLC owned approximately 0.05% of Thermo Fisher Scientific worth $98,161,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Fidelis Capital Partners LLC boosted its position in Thermo Fisher Scientific by 35.5% during the third quarter. Fidelis Capital Partners LLC now owns 5,522 shares of the medical research company’s stock worth $2,678,000 after purchasing an additional 1,448 shares during the period. New York State Common Retirement Fund lifted its stake in shares of Thermo Fisher Scientific by 0.4% during the 3rd quarter. New York State Common Retirement Fund now owns 491,917 shares of the medical research company’s stock valued at $238,590,000 after buying an additional 2,092 shares in the last quarter. TD Waterhouse Canada Inc. boosted its holdings in Thermo Fisher Scientific by 6.4% in the 3rd quarter. TD Waterhouse Canada Inc. now owns 33,980 shares of the medical research company’s stock worth $18,033,000 after buying an additional 2,050 shares during the period. Coastal Bridge Advisors LLC raised its holdings in Thermo Fisher Scientific by 45.5% during the 3rd quarter. Coastal Bridge Advisors LLC now owns 5,500 shares of the medical research company’s stock valued at $2,668,000 after acquiring an additional 1,719 shares during the period. Finally, Field & Main Bank lifted its position in shares of Thermo Fisher Scientific by 7.7% during the third quarter. Field & Main Bank now owns 1,922 shares of the medical research company’s stock worth $932,000 after acquiring an additional 138 shares in the last quarter. 89.23% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on the company. KeyCorp upgraded Thermo Fisher Scientific from a “sector weight” rating to an “overweight” rating and set a $750.00 price target for the company in a research report on Sunday, December 7th. Argus lifted their target price on Thermo Fisher Scientific from $580.00 to $610.00 and gave the company a “buy” rating in a report on Wednesday, October 29th. JPMorgan Chase & Co. increased their price target on shares of Thermo Fisher Scientific from $600.00 to $650.00 and gave the stock an “overweight” rating in a report on Thursday, October 9th. Evercore ISI restated an “outperform” rating and issued a $650.00 price objective on shares of Thermo Fisher Scientific in a research report on Monday, January 5th. Finally, Wells Fargo & Company upped their target price on shares of Thermo Fisher Scientific from $635.00 to $675.00 and gave the stock an “overweight” rating in a report on Monday, December 15th. One equities research analyst has rated the stock with a Strong Buy rating, eighteen have given a Buy rating and three have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, Thermo Fisher Scientific presently has a consensus rating of “Moderate Buy” and an average price target of $625.47.

Insider Buying and Selling

In other news, COO Michel Lagarde sold 22,046 shares of the company’s stock in a transaction dated Thursday, December 4th. The shares were sold at an average price of $563.56, for a total transaction of $12,424,243.76. Following the completion of the transaction, the chief operating officer directly owned 84,117 shares of the company’s stock, valued at approximately $47,404,976.52. This represents a 20.77% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, VP Lisa P. Britt sold 1,058 shares of the business’s stock in a transaction dated Wednesday, November 12th. The shares were sold at an average price of $588.26, for a total value of $622,379.08. Following the transaction, the vice president owned 13,087 shares in the company, valued at approximately $7,698,558.62. This represents a 7.48% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders sold 124,517 shares of company stock worth $72,363,568. 0.33% of the stock is owned by company insiders.

Thermo Fisher Scientific Stock Down 2.6%

TMO stock opened at $608.00 on Thursday. The company’s 50 day moving average is $593.74 and its 200 day moving average is $535.61. The stock has a market cap of $228.43 billion, a price-to-earnings ratio of 35.12, a price-to-earnings-growth ratio of 4.10 and a beta of 0.91. The company has a current ratio of 1.50, a quick ratio of 1.11 and a debt-to-equity ratio of 0.62. Thermo Fisher Scientific Inc. has a 1-year low of $385.46 and a 1-year high of $643.99.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings results on Thursday, January 29th. The medical research company reported $6.57 EPS for the quarter, topping analysts’ consensus estimates of $6.44 by $0.13. The business had revenue of $12.22 billion during the quarter, compared to analysts’ expectations of $11.95 billion. Thermo Fisher Scientific had a net margin of 15.02% and a return on equity of 16.97%. Sell-side analysts predict that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Thursday, January 15th. Shareholders of record on Monday, December 15th were given a $0.43 dividend. The ex-dividend date was Monday, December 15th. This represents a $1.72 annualized dividend and a yield of 0.3%. Thermo Fisher Scientific’s payout ratio is presently 9.94%.

Thermo Fisher Scientific declared that its Board of Directors has initiated a stock repurchase program on Thursday, November 6th that permits the company to repurchase $5.00 billion in shares. This repurchase authorization permits the medical research company to buy up to 2.4% of its shares through open market purchases. Shares repurchase programs are generally a sign that the company’s board believes its shares are undervalued.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.